NeoGenomics Resolves DOJ Investigation, Refocuses on Cancer Care
TipRanks (Mon, 20-Jul 5:47 PM ET)
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
Business Wire (Mon, 20-Jul 5:23 PM ET)
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
Business Wire (Thu, 9-Jul 7:05 AM ET)
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
Business Wire (Tue, 7-Jul 7:05 AM ET)
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
Business Wire (Thu, 25-Jun 7:05 AM ET)
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
Business Wire (Wed, 17-Jun 6:00 AM ET)
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
Business Wire (Mon, 15-Jun 5:24 PM ET)
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
Business Wire (Tue, 26-May 7:05 AM ET)
NeoGenomics to Participate in Upcoming Investor Conferences
Business Wire (Fri, 15-May 9:05 AM ET)
NeoGenomics Reports First Quarter 2026 Results
Business Wire (Tue, 28-Apr 4:05 PM ET)
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Neogenomics trades on the NASDAQ stock market under the symbol NEO.
As of July 21, 2026, NEO stock price climbed to $14.45 with 1,447,434 million shares trading.
NEO has a beta of 1.26, meaning it tends to be more sensitive to market movements. NEO has a correlation of 0.05 to the broad based SPY ETF.
NEO has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Neogenomics reported $187 million in Revenue and $.01 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.03.
In the last 3 years, NEO traded as high as $21.22 and as low as $4.72.
The top ETF exchange traded funds that NEO belongs to (by Net Assets): IJR, FBT, VTI, IWM, VB.
NEO has outperformed the market in the last year with a return of +131.6%, while the SPY ETF gained +20.4%. In the last 3 month period, NEO beat the market returning +75.6%, while SPY returned +5.9%. However, in the most recent 2 weeks NEO has underperformed the stock market by returning -4.7%, while SPY returned -0.4%.
NEO support price is $13.76 and resistance is $14.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEO shares will trade within this expected range on the day.